Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Titel:
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
Auteur:
Du, L. Yau, C. Brown-Swigart, L. Gould, R. Krings, G. Hirst, G.L. Bedrosian, I. Layman, R.M. Carter, J.M. Klein, M. Venters, S. Shad, S. van der Noordaa, M. Chien, A.J. Haddad, T. Isaacs, C. Pusztai, L. Albain, K. Nanda, R. Tripathy, D. Liu, M.C. Boughey, J. Schwab, R. Hylton, N. DeMichele, A. Perlmutter, J. Yee, D. Berry, D. van't Veer, L. Valero, V. Esserman, L.J. Symmans, W.F.